Who was tested / what changed
The studies answer different health questions
Which peptide did best? These unlike tests don't give one winner. Your concern needs a study that checked that concern.
Your health question determines which finding helps
Which finding relates to your health concern? Learn who took part, then find the health change measured. GLP-1 affects hunger and sugar, and semaglutide acts like that gut hormone. Tesamorelin increases growth hormone release, raising a further hormone that helps growth.
Certain semaglutide groups lost weight and had fewer severe heart or kidney illnesses [2][3][4]. Tesamorelin trials chiefly involved people with changes in fat storage related to HIV [6][8][10][11]. Your immune system fights infection, and HIV harms those defenses. Those fat results don't establish ordinary weight-loss benefits for everyone.
MOTS-c research tested mice and cells and measured people's blood [13][14][16][17]. These studies haven't proved a benefit from treating people. Comparing the results resembles comparing a lifting test with a running test. The tests can't settle all your possible health concerns.
Treatment trials in people cannot be replaced by mouse tests
Semaglutide changes hunger and sugar control by copying GLP-1. People received the drug in trials checking weight and serious illness. Your weight alone doesn't reveal whether your muscles stayed strong. Walking needs a test of how well you actually walk.
Growth hormone and a further hormone that helps growth increase after tesamorelin. Human trial scans showed reductions in liver fat and deeper belly fat. Chest-and-belly fat also fell in the patients with HIV. Extra muscle, organ and water weight doesn't establish muscle growth alone.
MOTS-c tests examined how cells use food to make energy. The treated mice had less muscle loss, improved muscle sugar use and better movement. Those tests didn't establish the same changes in treated people. Those gains don't establish how your own strength would change.
Changes inside cells leave human benefits to be tested
Semaglutide affects hunger and fullness, and people generally eat less. Trials also counted serious heart illness and major kidney problems [2][3][4]. Those were actual human illnesses, beyond changes inside cells. The patients' health still limits how findings apply to you.
After tesamorelin, your growth hormone rises along with a further hormone that helps growth. Scans showed reductions in liver fat and in fat deep within the belly [6][8]. Trials also found higher muscle, organ and water weight together. That doesn't establish how much muscle grew or became stronger.
When cells struggled to make energy, MOTS-c entered the nucleus (the part holding most DNA). Tests also found a muscle protein helping muscles take in sugar [13][17]. Other treated mice gained in running, grip and walking tests [16]. That doesn't prove your health would improve after receiving treatment.
Body weight cannot separate fat loss from other changes
Twenty twenty-one: STEP 1 studied adults without diabetes carrying extra weight. Average changes were −14.9% at 68 weeks with semaglutide and −2.4% with placebo, made without active medicine [4]. Both figures describe losses, with greater loss from semaglutide. You can't tell the separate fat and muscle losses here.
Twenty twenty-six: a review combined five tesamorelin trials in people with fat changes related to HIV. Patients had less fat in their livers, deep belly and middle. Muscle, organs and water weighed more when counted together [6]. Your own fat problem might differ from the problem tested.
Human trials here haven't shown MOTS-c weight loss or muscle gain. The tested mice lost less muscle and used sugar better [13]. Those mouse changes need testing with treatment in people next. They don't give you an estimate of human weight loss.
Mouse movement cannot establish easier walking for you
Mice given MOTS-c did better at running, walking and gripping [16]. Semaglutide and tesamorelin trials chiefly checked illness, weight or stored fat. The main purpose wasn't testing grip strength or walking in people. You can't rank walking benefits from studies that measured different changes.
A mouse movement test shows how that tested mouse moved. It doesn't establish your movement after receiving the substance. A trial counting fewer heart attacks provides evidence about human illness. Your strength question could still remain unanswered by that trial.
Cells using more energy doesn't mean you feel livelier during the day. Semaglutide mainly helps people eat less, while tesamorelin encourages fat breakdown. Growth hormone and a hormone that helps growth rise with tesamorelin. MOTS-c research explores food energy use in cells and muscles.
Feeling less tired needs checking in people who receive treatment. Cell tests can't show whether you have more daily energy. Nor can a mouse's running gain settle your tiredness. That human question remains separate from the cell findings.
Fewer human tests leave more safety questions open
Semaglutide has the broadest safety research of these three peptides. Stomach and bowel troubles and gallbladder disease are known concerns [5]. Fluid for digestion is held in your gallbladder. Rare cancer links involving the pancreas or thyroid aren't settled.
Tesamorelin trials support a limited use for fat changes related to HIV. A liver review judged harm to the liver unlikely [7]. Growth-related substances still prompt concerns about unwanted growth and changes in blood sugar. Stopping treatment allowed deep fat to return [10], so loss wasn't always lasting.
MOTS-c treatment has fewer human answers about benefit or harm. You can't compare harm rates without tests in treated people. Missing safety tests don't establish either certain harm or safety. Your safety question needs adequate human treatment studies.
Knowing who received treatment helps you judge each result
First, find out whether people, mice or cells were tested. Then check whether the people received treatment or only blood tests. Semaglutide trials counted serious heart illness and major kidney problems [2][3]. Those patients' illnesses might differ from your own health concern.
Tesamorelin scans measured separate fat stores beyond total body weight [6][8]. MOTS-c experiments chiefly tested mouse muscles and cells using food energy [13][16][17]. Changes in your weight can differ from changes in grip or walking. One improved result doesn't settle all those health questions.